Cantor Fitzgerald Predicts ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTVFree Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Artiva Biotherapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($2.72) per share for the year. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Artiva Biotherapeutics (NASDAQ:ARTVGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24).

ARTV has been the topic of a number of other research reports. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright initiated coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics presently has an average rating of “Buy” and an average target price of $21.00.

Read Our Latest Analysis on ARTV

Artiva Biotherapeutics Stock Down 7.4 %

ARTV opened at $6.55 on Wednesday. Artiva Biotherapeutics has a fifty-two week low of $6.35 and a fifty-two week high of $17.31. The business’s 50 day simple moving average is $10.49.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $623,000. BNP Paribas Financial Markets bought a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $42,000. MetLife Investment Management LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $135,000. Acuta Capital Partners LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $680,000. Finally, RTW Investments LP bought a new position in Artiva Biotherapeutics in the third quarter valued at approximately $2,300,000.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

See Also

Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.